**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

A 47-year-old woman developed severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) infection during treatment with fingolimod for relapsing-remitting multiple sclerosis \[*time to reaction onset not stated*\].

The woman was diagnosed with relapsing-remitting multiple sclerosis in 2010, followed by a sensory relapse in 2011. She started receiving fingolimod \[*dosage and route not stated*\] in 2011. No further relapses were noted and she was continued on fingolimod therapy. A new inflammatory lesion was noted on cervical MRI in 2018. She was regularly monitored, and no evidence of activation of a latent virus disease was noted in October 2019. She presented with a 7-day history of fever, dry cough and dyspnoea by the end of March 2020. Her RR was 30 /minute with a peripheral oxygen saturation (SpO~2~) of 87%. Bilateral multiple ground-glass opacities with a peripheral lung and sub-pleural distribution in the upper and lower lobes and bilateral interstitial pneumonia were noted on a chest CT scan.

The woman was treated with supplemental oxygen via oxygen mask yielding SpO~2~ of 93%. She was then admitted to the ICU. Physical examination showed RR of 28 /minute with fever on day 0 of hospitalisation. An elevated CRP level and peripheral lymphopenia were noted in laboratory tests. Her liver function test showed mild increase in AST and GGT levels. Also, the D-dimer level was high. Arterial blood gas analysis revealed pH 7.45, pCO~2~ 38mm Hg and paO~2~ of 83mm Hg. Oropharyngeal swab specimens showed positive results for SARS CoV-2, and its diagnosis was confirmed with quantitative reverse transcriptase-polymerase chain reaction targeting the RdRp-gene. There was no evidence of influenza or bacterial co-infection. Her fingolimod therapy was discontinued, and she was kept on non-invasive ventilation to provide oxygen and ventilation support regularly. Her oxygenation showed improvement 2 days later. Her RR was normal on day 4, and the nasal oxygen supply was reduced with an SpO~2~ of 96%. An improvement in peripheral consolidations in the lungs was noted in chest X-ray without further complications. She was shifted to the normal ward on day 5.
